Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy
Patrick Marcellin(Inserm), Nikolai V. Naoumov(Novartis (Switzerland)), Karsten Wursthorn(Medizinische Hochschule Hannover), Wan‐Long Chuang(Kaohsiung Medical University), Claudio Ávila, Aldo Trylesinski(Novartis (Switzerland)), Cheng‐Yuan Peng(China Medical University), Graham R. Foster(Queen Mary University of London), Mario Rizzetto(University of Turin), Rifaat Safadi(Hadassah Medical Center), Hugo Fainboim(Hospital Muñiz), Heiner Wedemeyer(Medizinische Hochschule Hannover), Edward Gane(University of Auckland), George Lau(Humanity & Health), Michael P. Manns(Medizinische Hochschule Hannover), Weibin Bao, Seng Gee Lim(National University of Singapore)
Cited by 62
Related Papers
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
|Hepatology|2003|2.7k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k